Medicus Sciences (MSAC) and Anteris Technology Cancel LOI

Medicus Sciences Acquisition Corp. (NASDAQ:MSAC) filed an 8-K this afternoon disclosing that its letter of intent (LOI) with medical technology company Anteris Technologies Ltd (“Anteris”) that was announced just last week, is now cancelled and the two parties are no longer discussing a possible transaction.

Anteris was required to make a public announcement on February 8 disclosing that it had been approached by the SPAC due to applicable Australian securities laws. However, the letter of intent was non-binding and the parties have quickly gone their separate ways.

Medicus Sciences has a little over a year left to find a target with a deadline of February 18, 2023, giving it plenty of time to still find a target and sign a DA.

Australia-based Anteris is a structural heart company helping healthcare professionals to create life-changing outcomes for patients through its Better Science and Better Design technologies.